Literature DB >> 18766447

Reproductive factors and hormone use and risk of adult gliomas.

Martha J Felini1, Andrew F Olshan, Jane C Schroeder, Susan E Carozza, Rei Miike, Terri Rice, Margaret Wrensch.   

Abstract

Previous research suggests there may be a hormonal influence on glioma risk as evidenced by lower rates in females, change in incidence rates around ages at menarche and menopause, and presence of hormone receptors in glial tumors. Using the large San Francisco Bay Area Adult Glioma Study, we investigated whether reported reproductive factors and hormone use were associated with gliomas overall or with histologic subtypes among female cases (n = 619) and controls (n = 650). We found that reproductive factors were generally not associated with gliomas. Weak to moderately elevated odds ratios were observed for self-reported later age at menarche (14+ vs. 12-13 years old: adjusted odds ratio (AOR) = 1.39, 95% confidence interval (CI): 1.02-1.89), particularly for non-glioblastoma histologies (AOR = 1.64, 95% CI: 1.11-2.43). Inverse associations were observed for ever self-reported use of exogenous hormones (oral contraceptive use: AOR = 0.72, 95% CI: 0.53-0.99; postmenopausal hormone use: AOR = 0.56, CI: 0.37-0.84). However, cumulative hormone exposure defined multiple ways demonstrated no clear pattern of association. The results of this study suggest that any protective effect of hormones on gliomas may be limited to exogenous hormones, but a more detailed history of exogenous hormone use is needed to confirm findings.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18766447      PMCID: PMC2881541          DOI: 10.1007/s10552-008-9220-z

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  43 in total

Review 1.  Classical and nonclassical estrogen action in the developing midbrain.

Authors:  E Küppers; T Ivanova; M Karolczak; N Lazarov; K Föhr; C Beyer
Journal:  Horm Behav       Date:  2001-09       Impact factor: 3.587

2.  Data, design, and background knowledge in etiologic inference.

Authors:  J M Robins
Journal:  Epidemiology       Date:  2001-05       Impact factor: 4.822

Review 3.  Oestrogen as a neuroprotective hormone.

Authors:  Christian Behl
Journal:  Nat Rev Neurosci       Date:  2002-06       Impact factor: 34.870

4.  EFFECTS OF DISTURBANCES IN THE HORMONAL STATUS ON EXPERIMENTAL BRAIN TUMORS.

Authors:  A P AVTSYN; L Y YABLONOVSKAYA
Journal:  Acta Unio Int Contra Cancrum       Date:  1964

5.  Lifetime estrogen exposure versus age at menopause as mortality predictor.

Authors:  Sophia C Jansen; Elisabeth H M Temme; Evert G Schouten
Journal:  Maturitas       Date:  2002-10-25       Impact factor: 4.342

6.  Inhibition of tumor growth by the antiangiogenic placental hormone, proliferin-related protein.

Authors:  N W Bengtson; D I Linzer
Journal:  Mol Endocrinol       Date:  2000-12

7.  History of allergies among adults with glioma and controls.

Authors:  Joseph L Wiemels; John K Wiencke; Jennette D Sison; Rei Miike; Alex McMillan; Margaret Wrensch
Journal:  Int J Cancer       Date:  2002-04-01       Impact factor: 7.396

8.  Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women.

Authors:  Miriam J J de Kleijn; Yvonne T van der Schouw; André L M Verbeek; Petra H M Peeters; Jan-Dirk Banga; Yolanda van der Graaf
Journal:  Am J Epidemiol       Date:  2002-02-15       Impact factor: 4.897

9.  2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta.

Authors:  Theresa M LaVallee; Xiaoguo H Zhan; Chris J Herbstritt; Emily C Kough; Shawn J Green; Victor S Pribluda
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

10.  Estrogen-astrocyte interactions: implications for neuroprotection.

Authors:  Krishnan M Dhandapani; Darrell W Brann
Journal:  BMC Neurosci       Date:  2002-06-07       Impact factor: 3.288

View more
  29 in total

1.  Reproductive factors and exogenous hormone use and risk of adult glioma in women in the NIH-AARP Diet and Health Study.

Authors:  Geoffrey C Kabat; Yikyung Park; Albert R Hollenbeck; Arthur Schatzkin; Thomas E Rohan
Journal:  Int J Cancer       Date:  2011-02-15       Impact factor: 7.396

2.  Joint associations between genetic variants and reproductive factors in glioma risk among women.

Authors:  Sophia S Wang; Patricia Hartge; Meredith Yeager; Tania Carreón; Avima M Ruder; Martha Linet; Peter D Inskip; Amanda Black; Ann W Hsing; Michael Alavanja; Laura Beane-Freeman; Mahboobeh Safaiean; Stephen J Chanock; Preetha Rajaraman
Journal:  Am J Epidemiol       Date:  2011-09-13       Impact factor: 4.897

3.  Hormonal contraceptive use and risk of glioma among younger women: a nationwide case-control study.

Authors:  Lene Andersen; Søren Friis; Jesper Hallas; Pernille Ravn; Bjarne W Kristensen; David Gaist
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

4.  Comment on Zong et al.: "Reproductive factors in relation to risk of brain tumors in women: an updated meta-analysis of 27 independent studies".

Authors:  Songshu Huang; Xiangrong Chen; Zunbin Ke; Junyan Chen
Journal:  Tumour Biol       Date:  2015-02-04

5.  Update on the effect of exogenous hormone use on glioma risk in women: a meta-analysis of case-control and cohort studies.

Authors:  Yu-Long Lan; Xun Wang; Jia-Cheng Lou; Bin-Bin Ma; Jin-Shan Xing; Shuang Zou; Bo Zhang
Journal:  J Neurooncol       Date:  2017-12-26       Impact factor: 4.130

6.  Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH and FAM20C.

Authors:  Jeanette E Eckel-Passow; Kristen L Drucker; Thomas M Kollmeyer; Matt L Kosel; Paul A Decker; Annette M Molinaro; Terri Rice; Corinne E Praska; Lauren Clark; Alissa Caron; Alexej Abyzov; Anthony Batzler; Jun S Song; Melike Pekmezci; Helen M Hansen; Lucie S McCoy; Paige M Bracci; Joseph Wiemels; John K Wiencke; Stephen Francis; Terry C Burns; Caterina Giannini; Daniel H Lachance; Margaret Wrensch; Robert B Jenkins
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

7.  Distinct germ line polymorphisms underlie glioma morphologic heterogeneity.

Authors:  Robert B Jenkins; Margaret R Wrensch; Derek Johnson; Brooke L Fridley; Paul A Decker; Yuanyuan Xiao; Thomas M Kollmeyer; Amanda L Rynearson; Stephanie Fink; Terri Rice; Lucie S McCoy; Chandralekha Halder; Matthew L Kosel; Caterina Giannini; Tarik Tihan; Brian P O'Neill; Daniel H Lachance; Ping Yang; Joseph Wiemels; John K Wiencke
Journal:  Cancer Genet       Date:  2011-01

8.  Effects of antihistamine and anti-inflammatory medication use on risk of specific glioma histologies.

Authors:  Michael E Scheurer; E Susan Amirian; Stacy L Davlin; Terri Rice; Margaret Wrensch; Melissa L Bondy
Journal:  Int J Cancer       Date:  2011-04-04       Impact factor: 7.396

9.  Inherited variation in immune genes and pathways and glioblastoma risk.

Authors:  Judith A Schwartzbaum; Yuanyuan Xiao; Yanhong Liu; Spyros Tsavachidis; Mitchel S Berger; Melissa L Bondy; Jeffrey S Chang; Susan M Chang; Paul A Decker; Bo Ding; Sarah J Hepworth; Richard S Houlston; Fay J Hosking; Robert B Jenkins; Matthew L Kosel; Lucie S McCoy; Patricia A McKinney; Kenneth Muir; Joe S Patoka; Michael Prados; Terri Rice; Lindsay B Robertson; Minouk J Schoemaker; Sanjay Shete; Anthony J Swerdlow; Joe L Wiemels; John K Wiencke; Ping Yang; Margaret R Wrensch
Journal:  Carcinogenesis       Date:  2010-07-28       Impact factor: 4.944

10.  Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.

Authors:  Margaret Wrensch; Robert B Jenkins; Jeffrey S Chang; Ru-Fang Yeh; Yuanyuan Xiao; Paul A Decker; Karla V Ballman; Mitchel Berger; Jan C Buckner; Susan Chang; Caterina Giannini; Chandralekha Halder; Thomas M Kollmeyer; Matthew L Kosel; Daniel H LaChance; Lucie McCoy; Brian P O'Neill; Joe Patoka; Alexander R Pico; Michael Prados; Charles Quesenberry; Terri Rice; Amanda L Rynearson; Ivan Smirnov; Tarik Tihan; Joe Wiemels; Ping Yang; John K Wiencke
Journal:  Nat Genet       Date:  2009-07-05       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.